Examining the activity of cefepime-taniborbactam against < em > Burkholderia cepacia < /em > complex and < em > Burkholderia gladioli < /em > isolated from cystic fibrosis patients in the United States
Antimicrob Agents Chemother. 2023 Sep 28:e0049823. doi: 10.1128/aac.00498-23. Online ahead of print.ABSTRACTThe novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Burkholderia gladioli strains. The addition of taniborbactam to cefepime shifted cefepime minimum inhibitory concentrations toward the provisionally susceptible range in 59% of the isolates tested. Therefore, cefepime-taniborbactam possessed similar activity as first-line agents, ceftazidime and trimethoprim-sulfamethoxazole, supporting further development.PMID:37768313 | DOI:10.1128/aac.00498-23
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Maria F Mojica Elise T Zeiser Scott A Becka John J LiPuma David A Six Greg Moeck Krisztina M Papp-Wallace Source Type: research
More News: Bactrim | Burkholderia | Burkholderia Cepacia | Chemotherapy | Cystic Fibrosis | Microbiology | Sulfamethoxazole | Trimethoprim | USA Health